---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-048347"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2026-07-15T20:58:01+00:00"
generated_at: "2026-07-15T20:59:10.720299+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crescent Biopharma prices $125M public offering of shares and pre-funded warrants

## Summary
- Priced 8,094,793 ordinary shares at $14.50/share and 525,897 pre-funded warrants at $14.499 each.
- Gross proceeds ~$125M; net proceeds ~$115.9M (~$133.5M if underwriters' option exercised in full).
- Underwriters granted 30-day option to purchase up to 1,293,103 additional ordinary shares.
- Net proceeds expected to fund operations into second half of 2028; closing expected July 16, 2026.
- Jefferies, TD Cowen, Guggenheim Securities, Cantor act as joint book-running managers.

## SEC filing metadata
- accession: 0001628280-26-048347
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2026-07-15T20:58:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/0001628280-26-048347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/cbio-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-048347
- JSON: https://secwatch.observer/filing/0001628280-26-048347.json
- Plain text: https://secwatch.observer/filing/0001628280-26-048347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.